Wednesday, September 22, 2021
Home > Slightly

Bitcoin (BTC) Price Slumps below $40K as Investor Sentiment Turns Slightly Bearish

The world’s leading crypto experienced a market sentiment shift after rallying nearly 44% in a week, defying predictions that it would dip further toward the $20K range. However, the momentum seems to be slowing down after BTC faced a rejection yesterday and ranked below $40K. As of this article’s writing,

Read More

ZM Shares Slightly Up Now as Zoom Agrees to $85M Settlement Over Privacy Breach

American communications technology company Zoom Video Communications Inc (NASDAQ: ZM) has agreed to an $85 million settlement to a class-action lawsuit in the United States. The lawsuit was centered on the violation of user’s privacy as the San Jose-based firm reportedly shared users data with Facebook Inc (NASDAQ: FB), Alphabet

Read More

JPMorgan says Bitcoin slightly overvalued as a commodity

Multiple JPMorgan Chase experts analyzed Bitcoin’s current price when compared to other commodities, and noted that the asset could see selling pressure ahead. “The JPMorgan strategists said they calculated an intrinsic value by effectively treating Bitcoin as a commodity and looking at the marginal cost of production,” according to an Oct.

Read More

AZN Stock Slightly Down, AstraZeneca Resumes Vaccine Trials in Japan

AstraZeneca’s clinical trials for the vaccine were halted in July after one of the participants complained of neurological disorder.Foremost COVID-19 vaccine pharmaceutical firm AstraZeneca Plc (LON: AZN) has disclosed that it has resumed its mid-late stage COVID-19 Vaccine trial in Japan, following the earlier global suspension of the process. As

Read More

AstraZeneca Resumes Trials for COVID-19 Vaccine, AZN Stock Slightly Up

In partnership with U.K.’s Oxford University, AstraZeneca said that it will resume the phase three clinical trial for its COVID-19 vaccine contender AZD1222 since it got an approval from UK’s Medicines Health Regulatory Authority. After pausing its work on the coronavirus vaccine citing safety concerns last week, pharmaceutical giant AstraZeneca plc

Read More